GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Kuros Biosciences Ltd (CHIX:KURNz) » Definitions » 3-Year FCF Growth Rate

Kuros Biosciences (CHIX:KURNZ) 3-Year FCF Growth Rate : 0.00% (As of Dec. 2024)


View and export this data going back to 2013. Start your Free Trial

What is Kuros Biosciences 3-Year FCF Growth Rate?

Kuros Biosciences's Free Cash Flow per Share for the six months ended in Dec. 2024 was CHF0.08.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.

During the past 13 years, the highest 3-Year average Free Cash Flow per Share Growth Rate of Kuros Biosciences was 76.70% per year. The lowest was -21.00% per year. And the median was 29.00% per year.


Competitive Comparison of Kuros Biosciences's 3-Year FCF Growth Rate

For the Medical Devices subindustry, Kuros Biosciences's 3-Year FCF Growth Rate, along with its competitors' market caps and 3-Year FCF Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Kuros Biosciences's 3-Year FCF Growth Rate Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Kuros Biosciences's 3-Year FCF Growth Rate distribution charts can be found below:

* The bar in red indicates where Kuros Biosciences's 3-Year FCF Growth Rate falls into.


;
;

Kuros Biosciences 3-Year FCF Growth Rate Calculation

This is the 3-year average growth rate of Free Cash Flow per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.


Kuros Biosciences  (CHIX:KURNz) 3-Year FCF Growth Rate Explanation

Free Cash Flow per Share is the amount of Free Cash Flow per outstanding share of the company's stock. Free Cash Flow is considered one of the most important parameters to measure a company's earnings power by value investors because it is not subject to estimates of Depreciation, Depletion and Amortization (DDA). However, when we look at the Free Cash Flow, we should look from a long term perspective, because any year's Free Cash Flow can be drastically affected by the spending on Property, Plant, & Equipment (PPE) of the business in that year. Over the long term, Free Cash Flow should give pretty good picture on the real earnings power of the company. It's used in the calculation of Forward Rate of Return (Yacktman) %.


Kuros Biosciences 3-Year FCF Growth Rate Related Terms

Thank you for viewing the detailed overview of Kuros Biosciences's 3-Year FCF Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


Kuros Biosciences Business Description

Traded in Other Exchanges
Address
Wagistrasse 25, Schlieren, Zurich, CHE, 8952
Kuros Biosciences Ltd is a Swiss-based biopharmaceutical company focused on the development of inventive products for tissue repair and bone regeneration. It operates through the following segments: Medical devices, Pharmaceuticals and Legacy portfolio. The Medical devices segment includes products such as MagnetOs and Attrax. The Pharmaceuticals segment includes products such as Fibrin-PTH, a drug-biologic combination that promotes targeted and controlled bone formation through the induction of osteoprogenitor cell differentiation, enhancement, of osteoblast proliferation and increasing the lifespan of bone-forming cells. The Legacy portfolio segment includes all other products that do not belong to the group's core business strategies.

Kuros Biosciences Headlines

No Headlines